You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 17, 2024

Investigational Drug Information for ASTX660


✉ Email this page to a colleague

« Back to Dashboard


What is the development status for investigational drug ASTX660?

ASTX660 is an investigational drug.

There have been 8 clinical trials for ASTX660. The most recent clinical trial was a Phase 1 trial, which was initiated on July 1st 2015.

The most common disease conditions in clinical trials are Lymphoma, Lymphoma, T-Cell, and Lymphoma, T-Cell, Peripheral. The leading clinical trial sponsors are Astex Pharmaceuticals, Inc., Otsuka Pharmaceutical Co., Ltd., and Cancer Research UK.

There are two US patents protecting this investigational drug and forty-four international patents.

Recent Clinical Trials for ASTX660
TitleSponsorPhase
A Study of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma (R/R PTCL)Astex Pharmaceuticals, Inc.Phase 1/Phase 2
Tolinapant and Radiation for Cisplatin-Ineligible, Previously Untreated, Locally Advanced Head and Neck CancerAstex Pharmaceuticals, Inc.Early Phase 1
Tolinapant and Radiation for Cisplatin-Ineligible, Previously Untreated, Locally Advanced Head and Neck CancerEmory UniversityEarly Phase 1

See all ASTX660 clinical trials

Clinical Trial Summary for ASTX660

Top disease conditions for ASTX660
Top clinical trial sponsors for ASTX660

See all ASTX660 clinical trials

US Patents for ASTX660

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
ASTX660 ⤷  Try a Trial Bicyclic heterocycle compounds and their uses in therapy ASTEX THERAPEUTICS LIMITED (Cambridge, GB) ⤷  Try a Trial
ASTX660 ⤷  Try a Trial Bicyclic heterocycle compounds and their uses in therapy ASTEX THERAPEUTICS LIMITED (Cambridge, GB) ⤷  Try a Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for ASTX660

Drugname Country Document Number Estimated Expiration Related US Patent
ASTX660 Argentina AR098838 2033-12-20 ⤷  Try a Trial
ASTX660 Australia AU2014369446 2033-12-20 ⤷  Try a Trial
ASTX660 Australia AU2019200840 2033-12-20 ⤷  Try a Trial
ASTX660 Brazil BR112016014561 2033-12-20 ⤷  Try a Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.